References
1 Agar NS, Wedgeworth E, Crichton S et al. Survival outcomes and prognostic factors in mycosis fungoides/Sezary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal.J Clin Oncol 2010. 28 : 4730-4739.
2 Lebowitz E, Geller S, Flores E et al. Survival, disease progression and prognostic factors in elderly patients with mycosis fungoides and Sezary syndrome: a retrospective analysis of 174 patients.J Eur Acad Dermatol Venereol 2019. 33 : 108-114.
3 Diamandidou E, Colome-Grimmer M, Fayad L et al. Transformation of mycosis fungoides/Sezary syndrome: clinical characteristics and prognosis. Blood 1998. 92 : 1150-1159.
4 Greer JP, Salhany KE, Cousar JB et al. Clinical features associated with transformation of cerebriform T-cell lymphoma to a large cell process. Hematol Oncol 1990. 8 : 215-227.
5 Barberio E, Thomas L, Skowron F et al. Transformed mycosis fungoides: clinicopathological features and outcome. Br J Dermatol 2007. 157 : 284-289.
6 Scarisbrick JJ, Prince HM, Vermeer MH et al. Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and Sezary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model. J Clin Oncol2015. 33 : 3766-3773.
7 Arulogun SO, Prince HM, Ng J et al. Long-term outcomes of patients with advanced-stage cutaneous T-cell lymphoma and large cell transformation. Blood 2008. 112 : 3082-3087.
8 Salhany KE, Cousar JB, Greer JP et al. Transformation of cutaneous T cell lymphoma to large cell lymphoma. A clinicopathologic and immunologic study. Am J Pathol 1988. 132 : 265-277.
9 Vergier B, de Muret A, Beylot-Barry M et al. Transformation of mycosis fungoides: clinicopathological and prognostic features of 45 cases. French Study Group of Cutaneious Lymphomas. Blood 2000.95 : 2212-2218.
10 Vural S, Akay BN, Botsali A et al. Transformation of Mycosis Fungoides/Sezary Syndrome: Clinical Characteristics and Prognosis.Turk J Haematol 2018. 35 : 35-41.
11 Talpur R, Sui D, Gangar P et al. Retrospective Analysis of Prognostic Factors in 187 Cases of Transformed Mycosis Fungoides.Clin Lymphoma Myeloma Leuk 2016. 16 : 49-56.
12 Bekkenk MW, Geelen FA, van Voorst Vader PC et al. Primary and secondary cutaneous CD30(+) lymphoproliferative disorders: a report from the Dutch Cutaneous Lymphoma Group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment. Blood2000. 95 : 3653-3661.
13 Kempf W, Pfaltz K, Vermeer MH et al. EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma. Blood 2011.118 : 4024-4035.
14 Benner MF, Willemze R. Applicability and prognostic value of the new TNM classification system in 135 patients with primary cutaneous anaplastic large cell lymphoma. Arch Dermatol 2009. 145 : 1399-1404.
15 Kadin ME, Hughey LC, Wood GS. Large-cell transformation of mycosis fungoides-differential diagnosis with implications for clinical management: a consensus statement of the US Cutaneous Lymphoma Consortium. J Am Acad Dermatol 2014. 70 : 374-376.
16 Willemze R, Kadin ME, Kempf W, Paulli M. Primary cutaneous CD30+ T-cell lymphoproliferative disorders. In: WHO Classification of Skin Tumours (Elder DE, Massi D, Scolyer RA, Willemze R, eds), 4th edn. Lyon: International Agency for Research on Cancer. 2018; 236-239.
17 Suga H, Sugaya M, Sato S. C-C chemokine receptor type 3 expression in lymphomatoid papulosis, but not in mycosis fungoides lesions from the same patient. Clin Exp Dermatol 2012. 37 : 75-77.
18 Suga H, Sugaya M, Miyagaki T et al. Differential patterns of CXCR3, CCR3, and CCR10 expression in mycosis fungoides, Sezary syndrome and CD30(+) lymphoproliferative disorders: immunohistochemical study of 43 samples. J Dermatol Sci 2011. 64 : 142-144.
19 Yamaguchi T, Ohshima K, Karube K et al. Expression of chemokines and chemokine receptors in cutaneous CD30+ lymphoproliferative disorders. Br J Dermatol 2006. 154 : 904-909.
20 Lai PJ HY, Hsu JD, Wey SJ. Early stage mycosis fungoides with focal CD30-positive large cell transformation. In: Dermatologica Sin [Internet] , Vol. 31. Taipei Elsevier Taiwan LLC. 2013; 73–77.
21 Ohtani T, Kikuchi K, Koizumi H et al. A case of CD30+ large-cell transformation in a patient with unilesional patch-stage mycosis fungoides. Int J Dermatol 2009. 48 : 623-626.
22 Watchorn RE, Pawade J, Wachsmuth RC. Unilesional CD30+ mycosis fungoides with large cell transformation and spontaneous regression, masquerading as verruca vulgaris. Clin Exp Dermatol 2018.43 : 633-635.
23 Besch-Stokes JG, Costello CM, Bhullar PK et al. Regression of mycosis fungoides with large-cell transformation following skin biopsy.J Eur Acad Dermatol Venereol 2020. 34 : e82-e84.